“Unclear” whether opioids are effective at treating cancer pain

Source: www.eurekalert.org Author: Peer-reviewed publication, University of Warwick The world’s largest review on opioid medicines for cancer pain has found it is unclear whether some commonly used opioid medicines are better than a placebo and suggests that non-opioid medicines, including aspirin, may be as effective as opioids. Researchers examining the data on opioids for pain caused by cancer have found surprisingly large gaps in evidence regarding the true benefits of these medicines for cancer pain. The study challenges the commonly held view that opioids are the most powerful pain relievers. The study, led by The University of Sydney and including The University of Warwick highlights that there is no ‘one size fits all’ treatment approach for cancer pain, urging health professionals and patients to carefully weigh up the evidence when deciding on a suitable pain management plan. Opioid pain relievers are the most common treatment for cancer pain management. Many international guidelines including the World Health Organization, recommend opioid medications to manage background cancer pain (constant pain) and breakthrough cancer pain (temporary flare-ups of pain in addition to background pain). However, the study found very few trials have compared commonly used opioid medicines with placebo. This included morphine, oxycodone and methadone. The study did not find convincing evidence that morphine was better or safer than other opioid medicines for background cancer pain outside of end-of-life care. This is despite morphine being widely viewed as the ‘gold standard treatment’ for cancer care by physicians and recommended in many international clinical guidelines [...]

2023-12-19T12:32:24-07:00December, 2023|Oral Cancer News|

Clinical trial gets oral cancer survivor through ‘mean’ cancer

Source: web.musc.edu Author: Leslie Cantu Brittany Person was reluctant to enroll in the clinical trial that her oncologist, John Kaczmar, M.D., recommended. Not because she was afraid of taking part in research, but because she just couldn’t deal with any more side effects. She'd already had every one in the book after being treated for a tongue cancer that had returned – and then returned again. “I was just coming off the tail end of chemo, where I had the worst side effects from the chemo and radiation. My body was just tired and beat up and scarred,” she said. When Kaczmar outlined the potential side effects of the investigational drug, she thought, “I just really don't want to do that again. That didn't sound like something I wanted to put myself through.” As she and her husband, Patrick Wilkin, drove from MUSC Hollings Cancer Center to Duke Cancer Institute for a second opinion, Person told Wilkin, “They need to tell me something crazy in order for me to do this trial.” That’s pretty much what they did. “The lady at Duke told me if I didn’t do anything, I would have six months to live,” Person said. “When we got the whole ‘six months to live’ talk, if you do nothing, or two years, if you do the standard immunotherapy, and that the experimental trial is your best shot at actually beating the thing, that's when Brittany and I were like, ‘Yeah, let's do this experimental trial,’” Wilkin said. [...]

2023-12-15T07:49:56-07:00December, 2023|Oral Cancer News|

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Source: medicalxpress.com/ Author: provided by University of Pittsburgh Schematic of our study design and cohort, which included a total of 120 patients who underwent head and neck surgery for various conditions. Lymphatic fluid from surgical drains, which is usually tossed in the trash, is a treasure in the hands of University of Pittsburgh and Washington University School of Medicine in St. Louis researchers who found that this liquid could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus (HPV). The new study, published in Clinical Cancer Research, shows for the first time that HPV DNA in lymphatic fluid collected after surgery is a powerful biomarker that could predict risk of cancer recurrence and help clinicians decide whether to ramp up adjuvant therapies or safely de-escalate treatment for patients with HPV-positive head and neck cancer. "Over the last decade, there has been emerging interest in liquid biopsy to pick up cancer recurrences after treatment," said senior author José P. Zevallos, M.D., M.P.H., professor and Eugene N. Myers, chair of the Department of Otolaryngology at the Pitt School of Medicine and UPMC Hillman Cancer Center. "Our goal was to bring liquid biopsy into the curative pathway for head and neck cancer so that we can use it not just to find recurrences but also to help make treatment decisions." Head and neck cancer once almost exclusively affected heavy drinkers and smokers, but the landscape of this disease has changed dramatically because of HPV, according [...]

2023-12-12T09:53:11-07:00December, 2023|Oral Cancer News|

Ultra-processed foods may increase cancer risks even more than we thought

Source: goodmenproject.com Author: Daniel T Cross We have long known that our diets can impact not only our environment but our health as well, and a new study confirms this. Eating more ultra-processed foods could put you at a higher risk of developing cancers of the upper aerodigestive tract, including the mouth, throat and esophagus, according to researchers at the University of Bristol and the International Agency for Research on Cancer. They reached this conclusion by analysing diet and lifestyle data on more than 450,000 adults whose dietary habits were followed for 14 years. Their study adds to the evidence base on the carcogenic effects of ultra-processed foods, which have already been linked to an increased risk of obesity, diabetes, heart disease and various forms of cancer. Results from the new research now indicate that eating 10% more ultra-processed foods is associated with a 23% higher risk of head and neck cancer and a 24% higher risk of a cancer of the esophagus. Increases in body fat accounted only for a small proportion of the statistical association between ultra-processed food consumption and the risk of these upper-aerodigestive tract cancers, according to the scientists. “Ultra-processed foods have been associated with excess weight and increased body fat in several observational studies. This makes sense as they are generally tasty, convenient and cheap, favouring the consumption of large portions and an excessive number of calories,” explains Fernanda Morales-Berstein, a PhD student at the University of Bristol who was the study’s lead author.

2023-12-10T08:19:41-07:00December, 2023|Oral Cancer News|

Common local anesthetic may be effective against head and neck cancers

Source: newatlas.com Author: Paul McClure A new study has uncovered how the commonly used local anesthetic drug, lidocaine, activates bitter taste receptors to exert an anti-cancer effect in head and neck cancers. Given its low cost and ready availability, the drug could easily be incorporated into the treatment of patients with this challenging form of cancer. Anyone who’s had a cut sutured up or a dental procedure such as a filling will probably be familiar with lidocaine (also known as lignocaine). While it’s known how the local anesthetic drug exerts its pain-inhibiting effects, it’s been suggested that lidocaine also has a beneficial effect on cancer patients, although how is not fully understood. Now, a study led by researchers at the University of Pennsylvania School of Medicine has solved a long-standing mystery of how lidocaine causes the death of certain cancer cells. “We’ve been following this line of research for years but were surprised to find that lidocaine targets the one receptor that happened to be mostly highly expressed across cancers,” said Robert Lee, a corresponding author of the study. That ‘one receptor’ is T2R14, a bitter taste receptor that’s expressed in head and neck squamous cell carcinomas (HNSCCs), cancers with a high mortality and significant treatment-related morbidity. HNSCCs arise in the mucosa of oral and nasal cavities due to exposure to environmental carcinogens and/or the human papillomavirus (HPV). In addition to their role in bitter taste perception, bitter taste receptors (T2Rs) are involved in innate immunity, thyroid function, cardiac physiology, [...]

2023-11-29T18:20:42-07:00November, 2023|Oral Cancer News|

Trial results support ‘new gold standard’ for head and neck cancer radiotherapy

Source: medicalxpress.com Author: Institute of Cancer Research Phase III trial results on a precision radiotherapy technique support a "new gold standard" for treating head and neck cancer patients. The research suggests the new approach can reduce the risk of swallowing problems after radiotherapy, without impacting the success of treatment. The Dysphagia-Aspiration Related Structures (DARS) trial compared dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) with standard IMRT. Reducing radiation to muscles involved in swallowing DO-IMRT optimizes IMRT to reduce the risk of swallowing difficulties, known as dysphagia. This common side effect of radiotherapy for head and neck cancer can, in some cases, leave patients needing a permanent feeding tube. DO-IMRT lowers the risk of dysphagia by reducing radiation to the pharyngeal muscles, which support swallowing. The DARS study included 112 newly diagnosed participants with oropharyngeal and hypopharyngeal cancers (tumors of the throat) from centers across the U.K. and Ireland. Half received standard IMRT and half received DO-IMRT for six weeks. Final results from the trial, which were published in The Lancet Oncology, revealed that: After two years, patients treated with DO-IMRT were more likely to report better swallowing function than those treated with IMRT. After a year, around three-fifths (62%) of DO-IMRT patients reported high normalcy of diet—meaning they were still able to eat at least some foods that require chewing—and more than 8 in 10 (85%) said they felt comfortable eating in public, compared with just under 45% and 75% of those treated with standard IMRT respectively. After just over three years of [...]

2023-11-26T15:49:43-07:00November, 2023|Oral Cancer News|

Despite treatment advances, oral mucositis continues to plague patients with head and neck cancer

Source: www.oncnursingnews.com Author: Lindsay Fischer Findings from a cohort study of patients with head and neck cancer (HNC) suggest that severe oral mucositis continues to be a common adverse event in this population. Findings were published in JAMA Network Open. In this single-institution study, 98.6% (n = 568) of patients who underwent definitive or adjuvant intensity-modulated RT (IMRT) for primary HNC between February 9, 2015, and May 2022, developed some degree of oral mucositis, and 62.5% (n = 360) of these patients developed severe oral mucositis. A total of 576 patients were included in this analysis. The median patient age was 62.5 years (IQR, 53.6-69.1) and 78.3% (n = 451) were male. Most patients were White (88.4%). Most patients (80.6%) also received concurrent chemotherapy. Quality-of-Life Parameters Patients were assessed for mouth and soreness (MTS) scores during radiotherapy through the Oral Mucositis Weekly Questionnaire–Head and Neck Cancer survey. Patients who had higher MTS scores were more likely to require a feeding tube (P = .001); the rate of feeding tube utilization with MTS scores 0, 1, 2, 3, and 4, respectively, was 0%, 3.6%, 6.6, 14.7%, and 21.6%. They were also more likely to be hospitalized (P = .02) or require opiate use (P

2023-11-22T13:11:21-07:00November, 2023|Oral Cancer News|

Hydration innovation: Scientists unveil groundbreaking dry mouth remedy

Source: scitechdaily.com Author: University of Leeds Proof of concept of new material for long-lasting relief from dry mouth conditions. A novel aqueous lubricant technology designed to help people who suffer from a dry mouth is between four and five times more effective than existing commercially available products, according to laboratory tests. Developed by scientists at the University of Leeds, the saliva substitute is described as comparable to natural saliva in the way it hydrates the mouth and acts as a lubricant when food is chewed. Microgel Technology Explained Under a powerful microscope, the molecules in the substance — known as a microgel — appear as a lattice-like network or sponge which bind onto the surface of the mouth. Surrounding the microgel is a polysaccharide-based hydrogel that traps water. This dual function will keep the mouth feeling hydrated for longer. Professor Anwesha Sarkar, who has led the development of the saliva substitute, said: “Our laboratory benchmarking reveals that this substance will have a longer-lasting effect. “The problem with many of the existing commercial products is they are only effective for short periods because they do not bind to the surface of the mouth, with people having to frequently reapply the substance, sometimes while they are talking or as they eat. “That affects people’s quality of life.” Study Findings and Benchmark Results Results from the laboratory evaluation, “Benchmarking of a microgel-reinforced hydrogel-based aqueous lubricant against commercial saliva substitutes,” are reported today (November 20) in the journal Scientific Reports. The performance of the [...]

2023-11-21T20:18:49-07:00November, 2023|Oral Cancer News|

Partnership to boost oral cancer early detection

Source: www.bitemagazine.com.au Author: staff Dental Health Services Victoria (DHSV) has partnered with the Royal Australian College of General Practitioners to ensure general practitioners across Australia have the tools they need to detect oral cancer early and save lives. A national online learning resource has been launched on the RACGP website to empower its members to identify individuals at risk of oral cancer, detect the disease earlier through screening and have important prevention conversations with patients. In Australia, there are more than 4000 new cases of head, neck and lip cancers diagnosed every year and the majority of these are oral cancers. In 2022, there were an estimated 2642 cases of lip and oral cancers with this figure expected to rise in the coming years. Largely due to delayed presentation or diagnosis, oral cancer carries low survival rates, which is why the Victorian Government’s 2016-20 Cancer Plan established the Oral Cancer Screening and Prevention Program to boost prevention and early detection of this disease. Funded by the Victorian Government, the program is led by DHSV in partnership with the University of Melbourne, La Trobe University, the Australian Dental Association (Victorian Branch) and the Victorian Department of Health. DHSV launched the Oral Cancer Learning Hub in 202—a practical and evidence-based resource that supports oral health professionals to recognise and refer suspected oral cancers in early stages for faster investigation, diagnosis and treatment. “Because GPs are often the first stop for Victorians seeking medical help, phase two of the program supports GPs to [...]

2023-11-15T15:10:04-07:00November, 2023|Oral Cancer News|

UK bioengineer designs tools to improve treatment for head and neck cancer

Source: uknow.uky.edu Author: Lindsay Travis One University of Kentucky researcher is working to develop new techniques for radiation treatment to improve survival rates of patients with a specific type of cancer. Caigang Zhu, Ph.D., is an assistant professor in the Department of Biomedical Engineering in the UK Stanley and Karen Pigman College of Engineering. He is also a member of the Molecular and Cellular Oncology Research Program at the UK Markey Cancer Center. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH) awarded Zhu a prestigious R01 grant of $2 million over five years to develop optical metabolic spectroscopy and imaging tools. Zhu is targeting head and neck squamous cell cancer. Squamous cells line the body's skin, mucous membranes and other tissues, including the mouth, throat and voice box. These types of cancers make up 4% of cases in the U.S., according to the National Cancer Institute. “Cellular metabolism is highly dynamic and strongly influenced by its local vascular microenvironment, gaining a systems-level view of tumor metabolism and vasculature in vivo is essential in understanding many critical cancer biology questions,” said Zhu Currently, there are few techniques to help oncologists answer those questions. Zhu’s Spectroscopic Imaging Laboratory, in the Pigman College of Engineering and supported by Markey, hopes to make a difference. Researchers in the lab will develop a new device to quickly measure tumor properties using a special fiber and smart techniques to map the blood vessels connected to them. “The team will [...]

2023-11-15T15:02:23-07:00November, 2023|Oral Cancer News|
Go to Top